• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Jan. 16

Dr Reddy’s Laboratories Ltd has launched Supanac (Diclofenac potassium 50 mg tablets) in the Indian market. The product, in-licensed from Applied Pharma Research (APR), Switzerland is used for acute pain management. The patented product has been developed by Dynamic Buffered Technology (DBT) making it a superior formulation of Diclofenac, which reaches peak plasma concentration approximately four times faster than Diclofenac enteric coated preparations thereby ensuri ng faster pain relief, according to a release. The Hyderabad-based pharma major already has two of its leading brands, Nise and Retoz, in the Non-Steroidal Anti-Inflammatory Drugs (NSAID). The NSAID market is estimated at Rs 2,700 crore and is growing at 20 per cent, the release added.

— Our Bureau

More Stories on : Announcements | New Products & Services | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ranbaxy 2006 research awards

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line